Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hui K. Gan"'
Autor:
Anatol Oleksijew, Thomas John, Diana Cao, Mark Anderson, Joann P. Palma, Kedar S. Vaidya, Puey-Ling Chia, Michael J. Mitten, Hugh D. Falls, Hui K Gan, Edward B. Reilly, Andrew M. Scott, Wenqing Gao, Erwin R. Boghaert
Publikováno v:
Molecular Cancer Therapeutics. 19:2117-2125
ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer toxin conjugated to the EGFR-targeting ABT-806 affinity-matured AM1 antibody. ABBV-321 follows th
Autor:
Chung-Ming Hsieh, Jonathan A. Meulbroek, Michael J. Mitten, Edward B. Reilly, Hui K Gan, David R. Reuter, Lorenzo Benatuil, Kenneth R. Durbin, Kedar S. Vaidya, Diana Cao, Devries Peter J, Erwin R. Boghaert, Sanjay C. Panchal, Andrew M. Scott, Martin J. Voorbach, Andrew C. Phillips, Hugh D. Falls, Fritz G. Buchanan, Sarah R. Mudd, Lise I. Loberg, Ralston Sherry L
Publikováno v:
Molecular cancer therapeutics. 17(4)
Depatuxizumab mafodotin (depatux-m, ABT-414) is a tumor-selective antibody drug conjugate (ADC) comprised of the anti-EGFR antibody ABT-806 and the monomethyl auristatin F (MMAF) warhead. Depatux-m has demonstrated promising clinical activity in glio
Autor:
Lusong Luo, Jason D. Lickliter, Michael Millward, Hui K Gan, Tarek Meniawy, Lai Wang, Jason Yang
Publikováno v:
Molecular Cancer Therapeutics. 14:PR11-PR11
This abstract has been withheld from publication due to its inclusion in the AACR-NCI-EORTC Molecular Targets Conference 2015 Official Press Program. It will be posted online at the time of its presentation in a press conference or in a session. Cita